儿科药学杂志2012，Vol.18Issue(8)：19-21,3.
孟鲁司特钠佐治小儿支原体肺炎的疗效观察
Clinical Observation on Montelukast as a Complement Therapy in Treating Pediatric Mycoplasma Pneumonia Infection
范晖1
作者信息
- 1. 广州中医药大学祈福医院,广东广州511495
- 折叠
摘要
Abstract
Objective: To discuss the clinical effects of montelukast as a complement therapy in treating in pediatric mycoplasma pneumonia (MP) infection. Methods: Ninety six pediatric patients with mycoplasma pneumonia (MP) infection in Pediatrics of Outpatient, Guangzhou University of Chinese Medicine, Clifford Hospital from Oct. 2009 to Oct. 2011, were randomly divide into treatment group (48 cases) and control group (48 cases). The control group were given sequential treatment of azitromycin, while the treatment group were given the above treatments and montelukast soudium 4 mg/d orally for 2 months. Take follow-ups for six months, and compare the clinical effects and adverse drug reactions of the two groups. Results: The total effective rates of the treatment group and the control group within 5 days were 89. 5% and 79. 1% , respectively. There were no statistical differences between the two groups (P>0.05). The rate of recurrent wheezing in the treatment group was obviously less than that in the control group in the follow-ups for six months, and none adverse reactions were found in the two groups. Conclusions: As an adjuvant treatment in pediatric MP infection, montelukast soudium can remarkably alleviate cough and wheezing, and decrease recurrence of disease with good compliance and few adverse reactions. It is worthy of clinical use.关键词
支原体/肺炎/孟鲁司特钠/喘息Key words
Mycoplasma/Pneumoniae/Montelukast soudium/Wheezing分类
医药卫生引用本文复制引用
范晖..孟鲁司特钠佐治小儿支原体肺炎的疗效观察[J].儿科药学杂志,2012,18(8):19-21,3.
